Home Neoplasma 2018 Neoplasma Vol.65, No.1, p.1-13, 2018

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.65, No.1, p.1-13, 2018

Title: MicroRNAs in triple-negative breast cancer
Author: M. KOLECKOVA, M. JANIKOVA, Z. KOLAR

Abstract: Triple-negative breast cancer (TNBC) is a molecular subtype of breast cancer with one of the worst prognoses. Current treatment is based on chemo- and/or radiotherapy and surgery. New targets, however, offering other therapeutic approaches, have been identified. These involve poly (ADP-ribose) polymerase (PARP), vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), androgen receptor (AR), long non-coding RNAs (lncRNAs) and microRNAs (miRs). The latter are non-coding RNAs which control the expression of more than 50% of human genes via regulation of basic cellular processes at post-transcriptional level and dysregulation of miRs is found in many types of tumors. The role of dysregulated miRs in carcinogenesis lies in their acting as tumor suppressors or oncogenes, and in resistance to treatment (chemotherapy, hormonal and targeted therapy or radiotherapy). Circulating miRs are also promising prognostic and predictive biomarkers in patients with breast cancer. The aim of this review is to analyze recently published data on miRs and therapeutic targets potentially influenced by miRs in TNBC.

Keywords: triple-negative breast cancer, microRNA, biomarkers, therapeutic targets
Published online: 11-Jan-2018
Year: 2018, Volume: 65, Issue: 1 Page From: 1, Page To: 13
doi:10.4149/neo_2018_170115N36
Price: 31.20 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.